Medical management of moyamoya disease and recurrent stroke in an infant with Majewski osteodysplastic primordial dwarfism type II (MOPD II)

Eur J Pediatr. 2012 Oct;171(10):1567-71. doi: 10.1007/s00431-012-1732-6. Epub 2012 Apr 17.

Abstract

We report an infant diagnosed with Majewski osteodysplastic primordial dwarfism type II at age 8 months, who experienced cerebrovascular morbidities related to this entity. Molecular analysis identified c.2609+1 G>A, intron 14, homozygous splice site mutation in the pericentrin gene. At age 18 months, she developed recurrent strokes and hemiparesis. Brain magnetic resonance imaging and magnetic resonance angiography showed abnormal gyral pattern, cortical acute infarcts, bilateral stenosis of the internal carotid arteries and reduced flow on the cerebral arteries, consistent with moyamoya disease. In Majewski osteodysplastic primordial dwarfism type II, life expectancy is reduced because of high risk of stroke secondary to cerebral vascular anomalies (aneurysms, moyamoya disease). Periodic screening for vascular events is recommended in individuals with Majewski osteodysplastic primordial dwarfism type II every 12-18 months following diagnosis. Our patient was medically managed with low molecular weight heparin followed with aspirin prophylaxis, in addition to carbamazepine and physical rehabilitation.

Conclusion: We report an infant with moyamoya disease and recurrent stroke presenting 10 months after diagnosis (at age 18 months), and discuss the outcome of nonsurgical medical management. The presented case is the second youngest case developing stroke and moyamoya disease.

Publication types

  • Case Reports

MeSH terms

  • Antigens / genetics
  • Carbamazepine / therapeutic use*
  • Dwarfism / complications*
  • Female
  • Fetal Growth Retardation
  • Heparin, Low-Molecular-Weight / therapeutic use*
  • Humans
  • Infant
  • Magnetic Resonance Angiography
  • Microcephaly / complications*
  • Moyamoya Disease / complications
  • Moyamoya Disease / drug therapy*
  • Osteochondrodysplasias / complications*
  • Recurrence
  • Stroke / drug therapy*
  • Stroke / etiology

Substances

  • Antigens
  • Heparin, Low-Molecular-Weight
  • pericentrin
  • Carbamazepine

Supplementary concepts

  • Microcephalic Osteodysplastic Primordial Dwarfism, Type II